Insiders · MNPR

MNPR insider transactions

Monopar Therapeutics Inc. (MNPR) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for MNPR

• 29d
  SEC Form 4 filed by Robinson Chandler

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 29d
  SEC Form 4 filed by Cittadine Andrew

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 58d
  SEC Form 4 filed by CCSO Rodriguez Susan

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 58d
  SEC Form 3 filed by new insider Rodriguez Susan

  3 - Monopar Therapeutics (0001645469) (Issuer)
• 91d
  Chief Executive Officer Robinson Chandler acquired 62,815 shares (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 116d
  Chief Executive Officer Robinson Chandler converted options into 8,724 shares and covered exercise/tax liability with 2,558 shares, increasing direct ownership by 8% to 85,718 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 116d
  Chief Operating Officer Cittadine Andrew converted options into 4,326 shares and covered exercise/tax liability with 1,889 shares, increasing direct ownership by 5% to 50,726 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 116d
  SEC Form 4 filed by Acting Chief Medical Officer Rioux Patrice

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 123d
  Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 133d
  Director Klausner Arthur J sold $343,889 worth of shares (5,121 units at $67.15), decreasing direct ownership by 37% to 8,762 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 135d
  Large owner Hendricks Diane disposed of 43,499 shares (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 135d
  Director Klausner Arthur J acquired 7,710 shares, increasing direct ownership by 125% to 13,883 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Chief Operating Officer Cittadine Andrew

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Director Starr Christopher M

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Director Klausner Arthur J

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Director Anderson Raymond

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Director Talukdar Lavina

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Director Tsuchimoto Kim R

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Chief Financial Officer Vu Quan Anh

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 144d
  SEC Form 4 filed by Chief Executive Officer Robinson Chandler

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 211d
  Chief Operating Officer Cittadine Andrew converted options into 4,327 shares and covered exercise/tax liability with 1,896 shares, increasing direct ownership by 5% to 48,289 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 211d
  Chief Executive Officer Robinson Chandler converted options into 8,726 shares and covered exercise/tax liability with 2,646 shares, increasing direct ownership by 8% to 79,552 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 217d
  Large owner Tactic Pharma Llc sold $34,999,957 worth of shares (550,229 units at $63.61) (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 289d
  Director Tsuchimoto Kim R exercised 8,904 in-the-money shares at a strike of $0.01 and sold $356,171 worth of shares (8,904 units at $40.00) (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 289d
  Director Starr Christopher M exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 289d
  Chief Executive Officer Robinson Chandler exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 303d
  Chief Executive Officer Robinson Chandler converted options into 13,344 shares and covered exercise/tax liability with 5,865 shares, increasing direct ownership by 11% to 73,472 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 303d
  Chief Operating Officer Cittadine Andrew converted options into 6,863 shares and covered exercise/tax liability with 2,990 shares, increasing direct ownership by 9% to 45,858 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 392d
  Large owner Tactic Pharma Llc sold $1,166,690 worth of shares (33,334 units at $35.00) (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 394d
  Chief Operating Officer Cittadine Andrew covered exercise/tax liability with 744 shares and converted options into 1,791 shares, increasing direct ownership by 3% to 41,985 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 394d
  Chief Executive Officer Robinson Chandler converted options into 4,106 shares and covered exercise/tax liability with 1,204 shares, increasing direct ownership by 5% to 65,993 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 420d
  Chief Executive Officer Robinson Chandler covered exercise/tax liability with 1,759 shares and converted options into 6,002 shares, increasing direct ownership by 7% to 63,091 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 420d
  SEC Form 4 filed by Chief Operating Officer Cittadine Andrew

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 420d
  SEC Form 4 filed by Director Starr Christopher M

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 420d
  SEC Form 4 filed by Director Klausner Arthur J

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 420d
  SEC Form 4 filed by Director Anderson Raymond

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 420d
  SEC Form 4 filed by Director Talukdar Lavina

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 420d
  SEC Form 4 filed by Director Tsuchimoto Kim R

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 421d
  New insider Talukdar Lavina claimed ownership of 14,001 shares (SEC Form 3)

  3 - Monopar Therapeutics (0001645469) (Issuer)
• 422d
  SEC Form 4 filed by Chief Financial Officer Vu Quan Anh

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 422d
  SEC Form 3 filed by new insider Vu Quan Anh

  3 - Monopar Therapeutics (0001645469) (Issuer)
• 484d
  SEC Form 4 filed by Acting Chief Medical Officer Rioux Patrice

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 484d
  Chief Operating Officer Cittadine Andrew converted options into 1,790 shares and covered exercise/tax liability with 721 shares, increasing direct ownership by 3% to 40,938 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 484d
  Chief Executive Officer Robinson Chandler converted options into 4,895 shares and covered exercise/tax liability with 2,209 shares, increasing direct ownership by 5% to 58,848 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 500d
  Large owner Tacticgem Llc disposed of 1,433,334 shares, closing all direct ownership in the company (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 548d
  Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 576d
  Chief Executive Officer Robinson Chandler converted options into 4,895 shares and covered exercise/tax liability with 1,918 shares, increasing direct ownership by 6% to 56,162 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 576d
  Chief Operating Officer Cittadine Andrew converted options into 1,791 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 3% to 39,869 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 667d
  SEC Form 4 filed by Chief Financial Officer Radhakrishnan Karthik

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 667d
  SEC Form 3 filed by new insider Radhakrishnan Karthik

  3 - Monopar Therapeutics (0001645469) (Issuer)
• 668d
  Chief Operating Officer Cittadine Andrew converted options into 8,952 shares and covered exercise/tax liability with 2,019 shares, increasing direct ownership by 4% to 193,065 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 668d
  Chief Financial Officer Tsuchimoto Kim R converted options into 9,957 shares and covered exercise/tax liability with 2,998 shares, increasing direct ownership by 14% to 57,429 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 668d
  Chief Executive Officer Robinson Chandler converted options into 24,476 shares and covered exercise/tax liability with 8,684 shares, increasing direct ownership by 6% to 265,923 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 679d
  Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 683d
  Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 695d
  Cittadine Andrew bought $18,480 worth of shares (24,000 units at $0.77), increasing direct ownership by 26% to 117,624 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 700d
  Cittadine Andrew bought $23,051 worth of shares (36,000 units at $0.64), increasing direct ownership by 62% to 93,624 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 701d
  Robinson Chandler exercised 84,000 in-the-money shares at a strike of $0.00, increasing direct ownership by 51% to 250,131 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 707d
  SEC Form 4 filed by Cittadine Andrew

  4 - Monopar Therapeutics (0001645469) (Issuer)
• 759d
  Cittadine Andrew converted options into 8,952 shares and covered exercise/tax liability with 3,098 shares, increasing direct ownership by 11% to 57,624 units (SEC Form 4)

  4 - Monopar Therapeutics (0001645469) (Issuer)